Navigation Links
Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males
Date:4/22/2009

Feedback Can Influence New Product Development and Innovation

MOUNTAIN VIEW, Calif., April 22 /PRNewswire/ -- The latest end-user study from Frost & Sullivan's Pharmaceuticals & Biotechnology group assesses a variety of critical dynamics of drug delivery approaches and technologies in cancer treatment. Physicians, nurses and patients provided insight on factors such as perception, usage, reconstitution, home vs. office administration parameters, and barriers of leading drug delivery types, providing insight and feedback to cancer treatment developers.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Selected findings from the survey include the following:

  • Nearly half of cancer patients surveyed wanted home infusion to last less than 1 hour.
  • Infusion nurses expected greater change in prescribing trends for cancer drug treatment over the next 12-24 months than oncologists.
  • Cancer patients were highly satisfied with implantable fusion pumps and oral delivery. While 75 percent of patients conduct drug delivery by themselves or a family member, oncologists and infusion nurses prefer this process be conducted by a trained healthcare worker or caregiver.
  • Oncologists and infusion nurses prefer oral as the leading type for new drug development, although other types were highly valued such as implants, transdermal patches, and implantable infusion pumps

Through more than 240 detailed interviews with medical oncologists, infusion nurses and cancer patients (breast, colorectal, lung, prostate) in the U.S., research analysts identified key insights into drug treatment, utilization, and potential future approaches to drug delivery in oncology.

From the Analyst

"Understanding the views and desires of end users regarding cancer drug delivery is an important asset to pharmaceutical and biotechnology companies," notes Frost & Sullivan Pharmaceuticals & Biotechnology Industry Manager Daniel Ruppar.

"As companies seek new opportunities in cancer treatment, an understanding of users' views of drug delivery factors from several sides could influence and generate innovative portfolio and development decisions," explains Ruppar. "By understanding the needs, preferences, and other points of feedback of the delivery of cancer drugs from oncologists, infusion nurses and patients, developers can glean insight from viewpoints across the cancer treatment pathway."

Resources

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Johanna Haynes
    Frost & Sullivan
    210-247-3870
    johanna.haynes@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Frost & Sullivan Applauds SHL Telemedicine for Excellence in Product Innovation
3. Frost & Sullivan Recognizes Kraton Polymers for Developing a New Generation of Polymer Grades Suitable for High-Speed Processing in Nonwoven Manufacture
4. Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications
5. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
6. Frost & Sullivan Award Highlights Opportunity for Main Street Biotech
7. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
8. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
9. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
10. Frost & Sullivan: In Vitro Diagnostics Market
11. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016   BioInformant announces the ... Cell Research Products, Opportunities, Tools, and Technologies – Market ... The first ... stem cell industry, BioInformant has more than a decade ... cell market, by stem cell type. This powerful 175 ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem ... agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection and ... countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, ...
(Date:2/10/2016)... Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... announce that Mitsui & Co. Ltd., its partner in ... plant, is investing an additional CDN$25 million in the ... stake from 30% to 40%.  Mitsui will also play ... produced in Sarnia , providing dedicated ...
(Date:2/10/2016)... Feb. 10, 2016  The Maryland House of Delegates ... announced that University of Maryland School of Medicine Dean ... University of Maryland Medical System President and CEO ... Medallion," the highest honor given to the public by ... Dean Reece and Mr. Chrencik for their ...
Breaking Biology Technology:
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Vigilant Solutions announces ... LPR data are being used by Lee,s Summit ... including the recent location and arrest of a homicide suspect. ... Summit covers around 65 square miles and is ... Police Department has a single mobile license plate reader ...
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market ... iris recognition is more widely accepted for ... with both fingerprint and iris recognition technology ... user to avoid purchasing two individual biometrics ...
(Date:2/9/2016)... Mass., Feb. 9, 2016 Aware, Inc. (NASDAQ: AWRE ... financial results for its fourth quarter and year ended December 31, ... for the fourth quarter of 2015 was $6.9 million, an increase ... year. Operating income in the fourth quarter of 2015 was $2.6 ... --> --> Higher revenue ...
Breaking Biology News(10 mins):